A Phase 2 interventional study of BL1107 Low dose and BL1107 High dose in Glaucoma, sponsored by Bausch & Lomb Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 490 studies in Glaucoma with a site in United States — 75 open to participants now, 94 under way, 5 of them phase 3. Glaucoma · United States.
Among the 490 studies in Glaucoma with a site in United States, this one is the 62nd largest by enrollment of the 364 interventional ones that give a count, is one of 29 that started in 2025, is one of 66 in phase 2, and was the 453rd registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →75 of the 490 studies in Glaucoma with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Tavo Biotherapeutics · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 30–90 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
490 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 88 · Phase 3 51 · Phase 4 66
First in 1976; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 79 across the 364 interventional studies, 100 across the 110 observational. Of the 358 that completed or were terminated, 138 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 490 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
Bausch Health Companies Inc. has 4 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
34 of the studies in Glaucoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT07510087Marc Toeteberg-HarmsGlaucoma Related Quality of Life | 2026-11-30 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT06615661Iantrek, Inc.A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 490 studies in Glaucoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of BL1107 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a randomized, double-masked, parallel comparison to evaluate two concentrations of BL1107 in both eyes compared with timolol 0.5% for 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BL1107 Low dose
Drug: BL1107 High dose
Drug: Timolol maleate 0.5%
Dosed twice daily for 28 days.
Dosed twice daily for 28 days.
Dosed twice daily for 28 days.
Change from baseline in visual field mean deviation in the study eye at Day 28/Exit.
Time frame: Assessed at Day 28
Proportion of participants achieving ≥15-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.
Time frame: Assessed at Day 28
Proportion of participants achieving ≥10-letter improvement in low-luminance best-corrected visual acuity (LL-BCVA) in the study eye at Day 28/Exit.
Time frame: Assessed at Day 28
Hour-matched change from Baseline in intraocular pressure (IOP) in the study eye at Day 28/Exit.
Time frame: Assessed at Day 28
Ran from Oct 2025 to primary completion in May 2026, 6 months.
Of 23 industry-sponsored phase 2 interventional studies under Glaucoma, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 11. This study's 6 months is below that.
Counting every sponsor, half of 32 studies reached it within 11 months; a quarter within 6 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.